PCI Biotech: Publication of preclinical tuberculosis results
11 janv. 2022 03h01 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 11 January 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that results from preclinical studies on tuberculosis performed in collaboration...
PCI Biotech and MDimune announce research collaboration agreement
05 janv. 2022 01h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway and Seoul, South Korea 5 January, 2022 – PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharmaceutical company and MDimune Inc. (“MDimune”), a private South Korean biotech company...
PCI Biotech to present at DNB Nordic Healthcare Conference 2021
14 déc. 2021 05h45 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 14 December 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech: Independent Data Monitoring Committee recommends continuation of two treatments in the RELEASE trial
13 déc. 2021 11h12 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 13 December 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the Independent Data Monitoring Committee (IDMC) has reviewed the safety...
PCI Biotech: Update on regulatory interactions for the RELEASE trial
07 déc. 2021 12h45 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 7 December 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the company has concluded on the interactions with regulatory authorities in...
PCI Biotech and Immunicum Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments
30 nov. 2021 02h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway, November 30, 2021 - PCI Biotech Holding ASA (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via Photochemical Internalisation and...
PCI Biotech to present at ABGSC Nordic Rare Disease Seminar
29 nov. 2021 05h07 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 29 November 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech Q3 2021 interim results
17 nov. 2021 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 17 November 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q3 2021 results. Please find enclosed the report and presentation. ...
PCI Biotech: Invitation to Q3 2021 result presentation
09 nov. 2021 06h50 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 9 November 2021 - PCI Biotech (OSE: PCIB) invites to a presentation of the company's Q3 2021 results on Wednesday 17 November 2021 at Oslo Cancer Cluster Innovation Park. Time:...
PCI Biotech to present at the 9th International mRNA Health Conference
09 nov. 2021 03h30 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 9 November 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...